At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,499 enrolled
Drug / intervention
Rimegepant +1 moredrug
Likely dose
Rimegepant 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
BHV3000-302 : Phase 3: Double-Blind, Randomized, Placebo-Controlled, Safety and Efficacy Trial of BHV-3000 (Rimegepant) for the Acute Treatment of Migraine
In Brief
A Phase 3 clinical trial evaluating Rimegepant and Placebo for Migraine, With or Without Aura. Completed, enrolled 1,499 participants across 50 sites.
Detailed Summary
The purpose of this study is to compare the efficacy of BHV-3000 (rimegepant) versus placebo in subjects with Acute Migraines
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
Enrollment StartJul 2017
First PostedAug 2017
Primary CompletionJan 2018
Study CompletionJan 2018
TodayJul 2026
First PostedAug 3, 2017
Enrollment StartJul 27, 2017
Primary CompletionJan 25, 2018
Study CompletionJan 31, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.9 years ago
Interventions
Rimegepantdrug
75 mg tablet QD
Placebodrug
Placebo tablet to match rimegepant dose QD